Top Markets
Coin of the day
Ceryvyn Therapeutics Ltd Ceryvyn Therapeutics Ltd

Ceryvyn Therapeutics Ltd

OPT
Hisse Senetlerindeki Sıralama #32057
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Hisse Fiyatı
$0.00846342
Son senkronizasyon: 2026-07-27
Piyasa Değeri
$11.27M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-97.73%
Ülke
AU
Ticaret Ceryvyn Therapeutics Ltd (OPT)

Kategori

Ceryvyn Therapeutics Ltd (OPT) için kazanç
2026 itibarıyla kazanç TTM: 0
Ceryvyn Therapeutics Ltd şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Ceryvyn Therapeutics Ltd için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR